Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study

Abstract Background This study aimed to evaluate the effects of Ischemic Compression Myofascial Trigger Points (IC-MTrPs) therapy, applied mainly to the upper trapezius muscle (UTM), on: [1] cervical spine range of motion (CS-ROM), and [2] headache characteristics in migraine patients. Reduced CS-RO...

Full description

Saved in:
Bibliographic Details
Main Authors: Maciej Olesiejuk, Małgorzata Chalimoniuk, Tomasz Sacewicz
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Musculoskeletal Disorders
Subjects:
Online Access:https://doi.org/10.1186/s12891-025-08360-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832572109443825664
author Maciej Olesiejuk
Małgorzata Chalimoniuk
Tomasz Sacewicz
author_facet Maciej Olesiejuk
Małgorzata Chalimoniuk
Tomasz Sacewicz
author_sort Maciej Olesiejuk
collection DOAJ
description Abstract Background This study aimed to evaluate the effects of Ischemic Compression Myofascial Trigger Points (IC-MTrPs) therapy, applied mainly to the upper trapezius muscle (UTM), on: [1] cervical spine range of motion (CS-ROM), and [2] headache characteristics in migraine patients. Reduced CS-ROM can further contribute to musculoskeletal strain and neurological discomfort in migraine sufferers. The application of IC-MTrPs therapy is of particular interest because it targets these trigger points, potentially normalizing muscle tone and improving local blood flow, which may alleviate pain and restore mobility. Design A case series employing a repeated-measures design; pilot study. Methods Fifty-three adult female migraine patients were classified into three groups: episodic migraine without aura (MO, n = 31), episodic migraine with aura (MA, n = 15), and chronic migraine (CM, n = 7). Patients underwent seven sessions of IC-MTrPs therapy targeting the shoulder and neck muscles. Assessments were conducted across five sessions: pre-therapy (baseline), post-1st therapy, post-4th therapy, post-7th therapy, and at a 1-month follow-up. Outcome measures included: CS-ROM (assessed using an accelerometer system), subjective headache pain intensity (evaluated via the Visual Analog Scale (VAS)), and calcitonin gene-related peptide (CGRP) concentrations. Results CS-ROM for horizontal rotation and forward flexion improved significantly at the 1-month follow-up compared to pre-therapy (baseline) (P < 0.05). Headache intensity during a migraine attacks, as well as headache frequency and duration, significantly decreased at post-7th therapy compared to baseline across all patients (P < 0.05). The highest CGRP concentrations were recorded in CM patients (240.73 ± 79.51 ng/ml). While no significant changes in CGRP levels were observed in patients with MO, CGRP concentration in patients with MA increased significantly at the 1-month follow-up compared to baseline, rising from 151.70 ± 50.85 ng/ml to 176.17 ± 77.21 ng/ml. In patients with CM, the therapy did not result in statistically significant changes in CGRP levels, although reductions in headache frequency and intensity were noted. Conclusions IC-MTrPs therapy proved effective in increasing CS-ROM and alleviating headache characteristics in all migraine subtypes. However, no significant changes in CGRP levels were observed. Distinct characteristics and responses among different migraine subtypes highlight the need for tailored therapeutic approaches. Trial registration The study protocol was retrospectively registered on December 2, 2022, as a clinical trial in the international clinical trial database ClinicalTrials.gov (identifier: NCT05646160). Clinical trial number: not applicable.
format Article
id doaj-art-f76b7d9ea2574cf68a17f0d168c91b3c
institution Kabale University
issn 1471-2474
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series BMC Musculoskeletal Disorders
spelling doaj-art-f76b7d9ea2574cf68a17f0d168c91b3c2025-02-02T12:05:25ZengBMCBMC Musculoskeletal Disorders1471-24742025-02-0126111310.1186/s12891-025-08360-1Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot studyMaciej Olesiejuk0Małgorzata Chalimoniuk1Tomasz Sacewicz2Department of Physical Education and Health in Biala Podlaska, Jozef Pilsudski University of Physical Education in Warsaw, Faculty in Biala PodlaskaDepartment of Physical Education and Health in Biala Podlaska, Jozef Pilsudski University of Physical Education in Warsaw, Faculty in Biala PodlaskaDepartment of Physical Education and Health in Biala Podlaska, Jozef Pilsudski University of Physical Education in Warsaw, Faculty in Biala PodlaskaAbstract Background This study aimed to evaluate the effects of Ischemic Compression Myofascial Trigger Points (IC-MTrPs) therapy, applied mainly to the upper trapezius muscle (UTM), on: [1] cervical spine range of motion (CS-ROM), and [2] headache characteristics in migraine patients. Reduced CS-ROM can further contribute to musculoskeletal strain and neurological discomfort in migraine sufferers. The application of IC-MTrPs therapy is of particular interest because it targets these trigger points, potentially normalizing muscle tone and improving local blood flow, which may alleviate pain and restore mobility. Design A case series employing a repeated-measures design; pilot study. Methods Fifty-three adult female migraine patients were classified into three groups: episodic migraine without aura (MO, n = 31), episodic migraine with aura (MA, n = 15), and chronic migraine (CM, n = 7). Patients underwent seven sessions of IC-MTrPs therapy targeting the shoulder and neck muscles. Assessments were conducted across five sessions: pre-therapy (baseline), post-1st therapy, post-4th therapy, post-7th therapy, and at a 1-month follow-up. Outcome measures included: CS-ROM (assessed using an accelerometer system), subjective headache pain intensity (evaluated via the Visual Analog Scale (VAS)), and calcitonin gene-related peptide (CGRP) concentrations. Results CS-ROM for horizontal rotation and forward flexion improved significantly at the 1-month follow-up compared to pre-therapy (baseline) (P < 0.05). Headache intensity during a migraine attacks, as well as headache frequency and duration, significantly decreased at post-7th therapy compared to baseline across all patients (P < 0.05). The highest CGRP concentrations were recorded in CM patients (240.73 ± 79.51 ng/ml). While no significant changes in CGRP levels were observed in patients with MO, CGRP concentration in patients with MA increased significantly at the 1-month follow-up compared to baseline, rising from 151.70 ± 50.85 ng/ml to 176.17 ± 77.21 ng/ml. In patients with CM, the therapy did not result in statistically significant changes in CGRP levels, although reductions in headache frequency and intensity were noted. Conclusions IC-MTrPs therapy proved effective in increasing CS-ROM and alleviating headache characteristics in all migraine subtypes. However, no significant changes in CGRP levels were observed. Distinct characteristics and responses among different migraine subtypes highlight the need for tailored therapeutic approaches. Trial registration The study protocol was retrospectively registered on December 2, 2022, as a clinical trial in the international clinical trial database ClinicalTrials.gov (identifier: NCT05646160). Clinical trial number: not applicable.https://doi.org/10.1186/s12891-025-08360-1MigrainePainHeadacheMyofascial trigger points (MTrPs)Ischemic compression (IC)Upper trapezius muscle (UTM)
spellingShingle Maciej Olesiejuk
Małgorzata Chalimoniuk
Tomasz Sacewicz
Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
BMC Musculoskeletal Disorders
Migraine
Pain
Headache
Myofascial trigger points (MTrPs)
Ischemic compression (IC)
Upper trapezius muscle (UTM)
title Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
title_full Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
title_fullStr Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
title_full_unstemmed Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
title_short Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients – pilot study
title_sort myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients pilot study
topic Migraine
Pain
Headache
Myofascial trigger points (MTrPs)
Ischemic compression (IC)
Upper trapezius muscle (UTM)
url https://doi.org/10.1186/s12891-025-08360-1
work_keys_str_mv AT maciejolesiejuk myofascialtriggerpointstherapyincreasesneckmobilityandreducesheadachepaininmigrainepatientspilotstudy
AT małgorzatachalimoniuk myofascialtriggerpointstherapyincreasesneckmobilityandreducesheadachepaininmigrainepatientspilotstudy
AT tomaszsacewicz myofascialtriggerpointstherapyincreasesneckmobilityandreducesheadachepaininmigrainepatientspilotstudy